Article
Multi-omic Analyses of Plasma Cytokines, Lipidomics, and Transcriptomics Distinguish Treatment Outcomes in Cutaneous Leishmaniasis
Registro en:
SANTOS, Hayna Malta et al. Multi-omic Analyses of Plasma Cytokines, Lipidomics, and Transcriptomics Distinguish Treatment Outcomes in Cutaneous Leishmaniasis. iScience, p. 1-30, 2020.
2589-0042
10.1016/j.isci.2020.101840
Autor
Santos, Hayna Malta
Fukutani, Kiyoshi Ferreira
Sorgi, Carlos A.
Queiroz, Artur Trancoso Lopo de
Nardini, Viviane
Silva, Juliana
Lago, Alex
Carvalho, Lucas Pedreira
Machado, Paulo L. R.
Bozza, Patrícia T.
Costa, Jaqueline França
Faccioli, Lúcia Helena
Carvalho, Edgar Marcelino
Andrade, Bruno de Bezerril
Borges, Valéria de Matos
Resumen
Leishmania braziliensis infection frequently results in cutaneous leishmaniasis (CL). An increase in incidence of drug-resistant CL leading to treatment failure has been reported. Identification of reliable predictors of treatment outcomes is necessary to optimize patient care. Here, we performed a prospective casecontrol study in which plasma levels of cytokines and lipid mediators were assessed at different time points during antileishmanial therapy in patients with CL from Brazil. Multidimensional analyses were employed to describe a combination of biomarkers able to predict and characterize treatment failure.We found a biosignature influencedmainly by plasma levels of lipidmediators that accurately predicted treatment failure. Furthermore, transcriptomic analysis of a publicly available data set revealed that expression levels of genes related to lipid metabolismmeasured in skin lesions could distinguish treatment outcomes in CL. Thus, activation of pathways linked to lipid biosynthesis predicts treatment failure in CL. The biomarkers identified may be further explored as therapeutic targets.